SequelSEC

Liminatus Pharma, Inc. LIMN

Biological Products, (No Diagnostic Substances) · CIK 0001971387 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$2.97M
Fiscal year ended 2025-12-31
Free cash flow
-$9.98M
Fiscal year ended 2025-12-31

Liminatus Pharma, Inc. (LIMN) reported net income of -$10.21M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Liminatus Pharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Liminatus Pharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
RevenueUnavailableUnavailable
Cost of revenueUnavailableUnavailable
Gross profitUnavailableUnavailable
Operating income-$2.97M-$3.33M
Net income-$10.21M-$3.55M
Research & developmentUnavailable$2.69M
Weighted-average diluted sharesshares 23.75Mshares 17.50M
Pretax incomeUnavailableUnavailable
Income tax expenseUnavailableUnavailable
Diluted EPS$-0.43$-0.20
Selling, general & administrativeUnavailableUnavailable
General & administrative$2.97M$644.62K
Selling & marketingUnavailableUnavailable

Balance

Liminatus Pharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalentsUnavailableUnavailable
Total assets$512.80K$5.41M
Current assets$500.57K$5.28M
Total liabilities$10.33M$24.75M
Current liabilities$10.30M$24.75M
Total equity incl. NCI-$9.81M-$19.34M
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivableUnavailableUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payableUnavailableUnavailable

Cash flow

Liminatus Pharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$9.96M-$1.45M
Capital expenditures$13.11KUnavailable
Investing cash flow-$788.11K-$2.85M
Financing cash flow$11.03M$3.92M
Net change in cash$281.34K-$378.07K
Stock-based compensationUnavailableUnavailable
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable

Derived

Liminatus Pharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flow-$9.98MUnavailable
Gross marginUnavailableUnavailable
Operating marginUnavailableUnavailable
FCF marginUnavailableUnavailable
SBC / revenueUnavailableUnavailable
Current ratio0.05x0.21x
Revenue YoY growthUnavailableUnavailable
Net marginUnavailableUnavailable
R&D / revenueUnavailableUnavailable
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LIMN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-10-06View SEC filing
10-Q · Filed 2025-06-02View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.